The emerging role of co-stimulatory molecules and their agonistic mAb-based combination therapies in melanoma

S He, J Xu, J Wu - International Immunopharmacology, 2020 - Elsevier
Abstract Although anti-PD-1/L1 and anti-CTLA-4 antibodies, the validated immune
checkpoint blockades, can elicit durable long-lasting antitumor immunity and improve the …
被引用次数：6 相关文章

The emerging role of co-stimulatory molecules and their agonistic mAb-based combination therapies in melanoma.

S He, J Xu, J Wu - International Immunopharmacology, 2020 - europepmc.org
Although anti-PD-1/L1 and anti-CTLA-4 antibodies, the validated immune checkpoint
blockades, can elicit durable long-lasting antitumor immunity and improve the clinical …

The emerging role of co-stimulatory molecules and their agonistic mAb-based combination therapies in melanoma

S He, J Xu, J Wu - International immunopharmacology, 2020 - pubmed.ncbi.nlm.nih.gov
Although anti-PD-1/L1 and anti-CTLA-4 antibodies, the validated immune checkpoint
blockades, can elicit durable long-lasting antitumor immunity and improve the clinical …